Brief: Lidds Says Study With Liproca Depot Meet Endpoints

Lidds AB

04/02/2021 09:09

Feb 4 (Reuters) - Lidds AB  LIDDS.ST :
    * EUROPEAN UROLOGY FOCUS HAS ACCEPTED A SCIENTIFIC ARTICLE
DESCRIBING LIDDS PHASE IIB STUDY RESULTS WITH LIPROCA® DEPOT
    * STUDY MET BOTH PRIMARY AND SECONDARY ENDPOINTS BY
CONFIRMING
EFFICACY AND SAFETY WITH LIPROCA DEPOT GIVEN AS INTRAPROSTATIC
INJECTION IN LOW- AND INTERMEDIATE RISK PROSTATE CANCER PATIENTS
    * LIPROCA® DEPOT IS WELL TOLERATED WITHOUT HORMONAL SIDE
EFFECTS
OTHERWISE ASSOCIATED WITH ANTI-ANDROGEN THERAPY AND IS EQUALLY
EASY TO ADMINISTER AS PERFORMING A PROSTATE BIOPSY

Source text for Eikon:  ID:nGNEc7bB0Q 
Further company coverage:  LIDDS.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))